Adverse drug reaction reports worldwide: 16,219
The World Health Organization Programme for International Drug Monitoring's database of adverse drug reactions (ADRs) currently contains 16,219 finasteride ADRs, including 3,102 reports of erectile dysfunction and 1,883 reports of sexual dysfunction. Additionally, the database contains 3,875 reports of psychiatric disorders, including 1,627 cases of depression and 1,307 cases of anxiety.
If you, or a loved one, have experienced any adverse reactions to finasteride and have not yet reported those reactions to your federal drug-regulatory agency(s), please access our Report Your Side Effects page and do so as soon as possible.
Known suicides worldwide: 63
The World Health Organization Programme for International Drug Monitoring’s database of adverse drug reactions currently contains 63 cases of completed suicide, 37 cases of suicide attempt and 331 cases of suicidal ideation.
If you know of any PFS patients who have taken their own lives, please email firstname.lastname@example.org. Please be prepared to furnish us with pertinent medical records, or with contact information for a family member who has such records, so that we may independently verify each case.
Nations warning of PFS: 23
In an August 2017 Periodic Safety Update, the European Medicines Agency (EMA) recommended that finasteride packaging be revised to include warnings of depression and suicidal ideation. In all, there are 31 EMA member states that could potentially take such action. To date, 13 of those states are known to have issued finasteride warnings. Additionally, four Asian, two Oceanian, one European, one North American, and two South American nations have similarly warned of PFS symptoms. Those 23 nations (in alphabetical order) are:
Argentina: National Pharmacovigilance System
Australia: Therapeutic Goods Administration (TGA Medicines Safety Update, 2013) (Propecia product insert)
Austria: Austrian Federal Office for Safety in Healthcare
Belgium: Federal Agency for Medicines and Health Products
Canada: Health Canada (February 2019) (June 2018)
Colombia: National Pharmacovigilance Program
Croatia: Agency for Medicinal Products and Medical Devices of Croatia
Denmark: Danish Medicines Agency
France: National Agency for the Safety of Medicine and Health Products (ANSM) (December 2019) (February 2019) (November 2017)
Germany: Federal Institute for Drugs and Medical Devices, Paul Ehrlich Institute
Ireland: Health Products Regulatory Authority
Israel: Pharmaceutical and Drug Information Department (June 2012) (December 2012)
Italy: Italian Pharmaceutical Agency
Malaysia: National Pharmaceutical Regulatory Agency
Montenegro: Agency for Medicines and Medical Devices
Netherlands: Dutch Medicines Evaluation Board
New Zealand: New Zealand Medicines and Medical Devices Authority
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Slovakia: State Institute for Drug Control
South Korea: Korean Ministry of Food and Drug Safety (English translation of data here)
Sweden: Medical Products Agency
United Arab Emirates: Ministry of Health and Prevention
United Kingdom: Medicines and Healthcare Products Regulatory Agency
If you know of any additional nations that have issued finasteride warnings, please email pertinent links to email@example.com.
PFS research studies published: 43
Over the past seven years, researchers at leading institutions—from Harvard Medical School to Northwestern University Feinberg School of Medicine to The George Washington University School of Medicine and Health Sciences—have published clinical studies and statistical analyses on PFS in leading journals, including JAAD, JAMA Dermatology, The Journal of Clinical Endocrinology & Metabolism, PeerJ, Pharmacotherapy and American Journal of Men's Health. To date, the PFS Foundation has aggregated 43 such papers on our Medical Literature page. Going forward, we will continue to review such literature and house it here for the edification of clinicians, researchers, patients and their family members, regulatory officials, and members of the media.
If you know of any additional PFS-related medical literature that you would like us to consider housing on our website, please email pertinent links to firstname.lastname@example.org.
Doctors and researchers speaking out worldwide: 45
A growing number of doctors, researchers and therapists have in recent years been voicing their concerns about finasteride’s potential to cause persistent physical and mental side effects, known as post-finasteride syndrome (PFS), in a subset of patients. To date, the PFS Foundation has identified 45 such professionals who have published scientific findings and/or voiced opinions on causative links between finasteride and PFS. Those findings and opinions can be reviewed on our Doctors & Researchers Speaking Out page. Some of these same doctors and researchers are also members of our Medical Professionals team, counseling PFS patients and their loved ones worldwide.
If you know of any additional doctors, researchers and/or therapists who have published warnings of persistent side effects stemming from finasteride use, and/or if you would like to suggest adding a medical professional to our Medical Professionals list, please email pertinent links/names to email@example.com.
National media reports worldwide: 267
The PFS Foundation tracks global media coverage of post-finasteride syndrome on an ongoing basis. We then house significant media reports about the condition on our PFS Media Awareness page. To date, we have aggregated 267 national media reports and 45 local and/or trade media reports.
If you know of any PFS media reports, in any language, that are not currently housed on our PFS Media Awareness page, please email pertinent links to media@PFSFoundation.org.
Years finasteride on the market: 26
Proscar (finasteride 5-mg), a prescription medication used to treat enlarged prostate in men, was approved by the US Food and Drug Administration on April 5, 1993.
Propecia (finasteride 1-mg), a prescription medication used to treat male pattern hair loss, was approved by the US Food and Drug Administration on December 19, 1997.